Laservision.gr Institute, Athens, Greece.
J Refract Surg. 2009 Nov;25(11):1034-7. doi: 10.3928/1081597X-20090901-02.
To evaluate the safety and efficacy of a novel femtosecond laser-assisted technique for intrastromal administration of riboflavin and higher fluence ultraviolet a (UVA) light in collagen cross-linking (CXL) for keratoconus.
Ten eyes with early keratoconus were treated with CXL and followed for a mean of 26 months (range: 18 to 36 months). Using a femtosecond laser, a 100-microm deep, 7-mm diameter intrastromal pocket was created. Two 0.1-mL doses of 0.1% riboflavin solution were infused into the pocket and the cornea was irradiated with 7 mW/cm2 UVA light of mean 370 nm wavelength for 15 minutes.
Mean uncorrected visual acuity improved from 20/40.5 to 20/32.5 best spectacle-corrected visual acuity was unchanged at 20/20, mean sphere was reduced by 0.50 diopters (D), mean cylinder was reduced by 0.90 D, and maximum mean keratometry (K) reduced from 48.7 to 47.90 D. No ectasia progression (defined as increase in K over 3-month follow-up) and no statistically significant change in endothelial cell count was noted during follow-up. The mean thinnest corneal thickness appeared to initially reduce but the mean returned to at least the preoperative level by 18 months. All patients returned to full activities within 1 day postoperative. No adverse effects were noted in any of the cases studies.
This novel epithelium-sparing, rapid soak-and-treat method of intrastromal riboflavin instillation and higher fluence UVA light for CXL appears to be safe and effective. No negative biomechanical effect (ectasia/epithelial ingrowth) was noted due to the femtosecond laser-created pocket. Because minimal epithelial injury occurs using this technique, postoperative pain appears to be significantly reduced.
评估一种新型飞秒激光辅助技术在基质内给予核黄素和更高强度的紫外线 A(UVA)光进行胶原交联(CXL)治疗圆锥角膜的安全性和有效性。
对 10 只早期圆锥角膜眼进行 CXL 治疗,平均随访 26 个月(范围:18 至 36 个月)。使用飞秒激光在基质内创建一个 100 微米深、7 毫米直径的基质口袋。将 0.1%核黄素溶液的 2 个 0.1 毫升剂量注入口袋中,并用平均 370nm 波长 7mW/cm2 的 UVA 光照射 15 分钟。
平均未矫正视力从 20/40.5 提高到 20/32.5,最佳矫正视力保持不变,为 20/20,平均球镜减少 0.50 屈光度(D),平均柱镜减少 0.90 D,最大平均角膜曲率(K)从 48.7 减少到 47.90 D。在随访期间未发现角膜扩张进展(定义为 3 个月随访时 K 值增加),也未发现内皮细胞计数有统计学意义的变化。角膜最薄厚度的平均值似乎最初减少,但在 18 个月时平均值至少恢复到术前水平。所有患者术后 1 天内均可恢复正常活动。在所有研究病例中均未发现不良反应。
这种新型的上皮下、快速浸泡和治疗的基质内核黄素滴注和更高强度 UVA 光用于 CXL 的方法似乎是安全有效的。由于飞秒激光创建的口袋,未观察到负性生物力学效应(扩张/上皮内生长)。由于该技术对上皮造成的损伤最小,术后疼痛明显减轻。